Abstract:More than 10% of nasopharyngeal cancer (NPC) patients develop local recurrence after definitive radiotherapy or chemoradiation. Re-irradiation (re-RT) with X-ray-based intensity-modulated radiotherapy (IMXT) is the most accepted treatment for salvaging locally recurrent NPC (LR-NPC) especially for those at locally advanced stages. However, the reported 2-year overall survival (OS) rates only ranged between 45∼60% for locally advanced LR-NPC after salvage IMXT largely due to treatment-induced toxicities. Due to its inherent physical and biological advantages, carbon-ion radiotherapy (CIRT) is feasible and potentially effective for LR-NPC. Here we report the 1-year outcomes of our phase I/II trial in terms of survival, disease control, and toxicities of LR-NPC patients treated at the maximal tolerable dose (MDT) of CIRT re-RT. This open-label single arm phase I/II trial enrolled pathologically and/or clinically confirmed LR-NPC (age 18∼70 years) diagnosed >12 months after the completion of initial IMXT. In the phase I study, the Time-to-Event Continual Reassessment Method was used to determine, via a dose-escalation scheme, the MTD of CIRT re-RT. The primary end point of the phase II part was patients' 2-year OS. Severe (i.e., Grade 4 or 5) acute and subacute toxicities were analyzed. All patents were treated at 3 Grey Equivalent (GyE) per daily fraction, 5 days a week, using intensity-modulated CIRT with raster-scanning technology. Neoadjuvant chemotherapy (cisplatin + docetaxel or gemcitabine) was recommended for patients with stage III-IVA/B LR-NPC, but concurrent chemotherapy was prohibited. Sixteen patients were accrued to the phase I dose escalating (range 51∼63GyE in 17∼21 fractions) protocol. No patient experienced grade 4 toxicities, thus the MTD was set at 63 GyE/21 fractions, the highest of the protocol dose scheme. Thirty-nine LR-NPC patients (AJCC stage I/II/III/IVA-B disease in 4/8/10/17 patients) were accrued to the phase II study. All patients completed planned 63GyE/21 daily fractions without break. With a median follow-up of 8.4 (range 2.0∼21.9) months, 1 patient died from massive hemorrhage subsequent to mucosal necrosis. The 1-year overall, local progression-free, regional recurrence-free, and distant metastasis free survival rates were 95.0%, 87.1%, 96.4%, and 100%, respectively. No patient experienced acute toxicity of ≥ grade 3. Grade 3 or above late toxicities observed included mucosal necrosis (5.1%), xerostomia (2.6%), hearing loss (5.1%), and temporal lobe necrosis (2.6%). This was the first prospective clinical trial to evaluate the efficacy and safety of CIRT for LR-NPC. Our results suggested that CIRT provided promising OS at 1 year with infrequent severe toxicities.

Mouse nerve growth factor in the treatment of radiation-induced cerebral necrosis

Treatment Of Brain Radiation Necrosis With Mouse-Nerve Growth Factor: A Phase Ii Trial

Treatment of Cerebral Radiation Necrosis with Nerve Growth Factor: A Prospective, Randomized, Controlled Phase II Study.

~1H-MRS study on radiation-induced injury of the brain in early acute reaction stage after nasopharyngeal carcinoma radiotherapy

Mouse Nerve Growth Factor for Treating Dysphagia Induced by Radiotherapy in Patients with Nasopharyngeal Carcinoma

Alleviating Visual Impairment from Radiation-Induced Optic Neuropathy by Mouse Nerve Growth Factor

Dynamic MRI Follow-Up of Radiation Encephalopathy in the Temporal Lobe Following Nasopharyngeal Carcinoma Radiotherapy

Phase I/II Trial Evaluating Carbon-Ion Radiotherapy for Salvage Treatment of Locally Recurrent Nasopharyngeal Carcinoma

Clinical Observation on Mouse Nerve Growth Factor in the Prevention of Dysfunction of Cerebral Trauma

Gamma Ray‐induced Glial Activation and Neuronal Loss Occur Before the Delayed Onset of Brain Necrosis

Mouse nerve growth factor promotes neurological recovery in patients with acute intracerebral hemorrhage: A proof-of-concept study.

Radiation-induced Gray Matter Atrophy in Patients with Nasopharyngeal Carcinoma after Intensity Modulated Radiotherapy: a MRI Magnetic Resonance Imaging Voxel-Based Morphometry Study.

Comparison between high-dose and low-dose intravenous methylprednisolone therapy in patients with brain necrosis after radiotherapy for nasopharyngeal carcinoma.

Neuroprotective Effect of Intranasal Administration of Nerve Growth Factor in the Mouse MPTP Model of Parkinson's Disease

Comprehensive Treatment of Radiation-Induced Lower Cranial Neuropathy in Patients with Nasopharyngcal Carcinoma: a Clinical Analysis

The Clinical Study of the Safety and Efficacy of Mouse Nerve Growth Factor in Treatment of Moderate and Severe Head Trauma

Effect of edaravone on radiation-induced brain necrosis in patients with nasopharyngeal carcinoma after radiotherapy: a randomized controlled trial

Therapeutic Effect of Mouse Nerve Growth Factor on 2, 5-Hexanedione Intoxicated Peripheral Neuropathy in Rats

Intranasal Delivery of Nerve Growth Factor to Protect the Central Nervous System Against Acute Cerebral Infarction.

Radiation-induced nasopharyngeal necrosis in locally-recurrent nasopharyngeal carcinoma patients after re-radiotherapy.

Inhibitors of HIF-1α and CXCR4 Mitigate the Development of Radiation Necrosis in Mouse Brain.